€30m raised for first-in-class in vivo cell reprogramming platform
Drug Discovery World
MARCH 19, 2024
The company plans to submit an Investigational New Drug (IND) application to the FDA for AT-108 by 2026, expand and reinforce its research and development team, and fuel new reprogramming modalities and delivery platforms to strengthen the pipeline. This financing also follows a strong pre-clinical package providing PoC for AT-108.
130 
Let's personalize your content